The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Department of Pathology and Pathophysiology, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China; The Second Hospital of Lanzhou University, Lanzhou, China.
Cytotherapy. 2024 Jan;26(1):1-10. doi: 10.1016/j.jcyt.2023.09.002. Epub 2023 Oct 7.
Exosome therapy for traumatic spinal cord injury (TSCI) is a current research hotspot, but its therapeutic effect and the best source of stem cells for exosomes are unclear.
The Web of Science, PubMed, Embase, Cochrane, and Scopus databases were searched from inception to March 28, 2023. Literature screening, data extraction and risk of bias assessment were performed independently by two investigators.
A total of 40 studies were included for data analysis. The findings of our traditional meta-analysis indicate that exosomes derived from stem cells significantly improve the motor function of TSCI at various time points (1 week: weighted mean difference [WMD] = 1.58, 95% confidence interval [CI] 0.87-2.30] 2 weeks: WMD = 3.12, 95% CI 2.64-3.61; 3 weeks: WMD = 4.44, 95% CI 3.27-5.60; 4 weeks: WMD = 4.54, 95% CI 3.42-5.66). Four kinds of stem cell-derived exosomes have been studied: bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, umbilical cord mesenchymal stem cells and neural stem cells. The results of the network meta-analysis showed that there was no significant statistical difference in the therapeutic effect among the exosomes derived from four kinds of stem cells at different treatment time points. Although exosomes derived from bone marrow mesenchymal stem cells are the current research focus, exosomes derived from neural stem cells have the most therapeutic potential and should become the focus of future attention.
The exosomes derived from stem cells can significantly improve the motor function of TSCI rats, and the exosomes derived from neural stem cells have the most therapeutic potential. However, the lower evidence quality of animal studies limits the reliability of experimental results, emphasizing the need for more high-quality, direct comparative studies to explore the therapeutic efficacy of exosomes and the best source of stem cells.
外体治疗创伤性脊髓损伤(TSCI)是当前的研究热点,但外体的治疗效果和最佳干细胞来源尚不清楚。
从建库到 2023 年 3 月 28 日,我们在 Web of Science、PubMed、Embase、Cochrane 和 Scopus 数据库中进行了检索。两名调查员独立进行了文献筛选、数据提取和偏倚风险评估。
共有 40 项研究纳入数据分析。我们的传统荟萃分析结果表明,干细胞来源的外体在不同时间点显著改善 TSCI 的运动功能(1 周:加权均数差 [WMD] = 1.58,95%置信区间 [CI] 0.87-2.30;2 周:WMD = 3.12,95% CI 2.64-3.61;3 周:WMD = 4.44,95% CI 3.27-5.60;4 周:WMD = 4.54,95% CI 3.42-5.66)。已经研究了四种干细胞来源的外体:骨髓间充质干细胞、脂肪间充质干细胞、脐带间充质干细胞和神经干细胞。网络荟萃分析的结果表明,在不同治疗时间点,四种干细胞来源的外体的治疗效果没有显著的统计学差异。虽然骨髓间充质干细胞来源的外体是当前的研究重点,但神经干细胞来源的外体具有最大的治疗潜力,应该成为未来关注的焦点。
干细胞来源的外体可显著改善 TSCI 大鼠的运动功能,神经干细胞来源的外体具有最大的治疗潜力。然而,动物研究证据质量较低限制了实验结果的可靠性,强调需要更多高质量、直接比较的研究来探索外体的治疗效果和最佳的干细胞来源。